Kera Capital Partners Inc. Acquires New Holdings in Cencora, Inc. (NYSE:COR)

Kera Capital Partners Inc. purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,148 shares of the company's stock, valued at approximately $258,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. lifted its position in Cencora by 6,855.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after acquiring an additional 2,035,679 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Cencora by 136.8% in the second quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock valued at $153,623,000 after purchasing an additional 370,841 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after purchasing an additional 338,452 shares during the last quarter. Nordea Investment Management AB grew its position in Cencora by 40.2% in the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after purchasing an additional 308,773 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in Cencora by 21.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after buying an additional 292,600 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

COR has been the subject of several analyst reports. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Evercore ISI upped their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Wells Fargo & Company lowered their price objective on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research note on Friday, December 13th. Finally, Robert W. Baird raised their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $275.60.

Cencora Stock Performance

Shares of COR stock traded up $1.22 on Friday, hitting $242.11. The company's stock had a trading volume of 1,492,998 shares, compared to its average volume of 993,012. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The stock's 50 day moving average is $237.52 and its 200-day moving average is $234.01. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a market capitalization of $46.80 billion, a PE ratio of 32.24, a PEG ratio of 1.48 and a beta of 0.49.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora's dividend payout ratio is 29.29%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock worth $22,862,734 over the last ninety days. Corporate insiders own 15.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.